To provide long-term capital growth.
Name | % Net Assets |
---|---|
Concurrent Technologies | 4.7% |
AstraZeneca | 4.5% |
Wilmington | 4.3% |
Glaxosmithkline | 4.0% |
Spirax Sarco Engineering | 3.9% |
RWS Holdings | 3.9% |
Cobham | 3.7% |
Next Fifteen Communications | 3.6% |
Brooks MacDonald | 3.2% |
Renishaw | 3.2% |
Key | % Net Assets |
---|---|
![]() |
4.7% |
![]() |
4.5% |
![]() |
4.3% |
![]() |
4.0% |
![]() |
82.5% |
Date | 14-Feb-2025 |
---|---|
Bid | 495.24p |
Offer | 499.42p |
Currency | GBP |
Change | 1.17p |
% | 0.24% |
YTD change | 14.70p |
YTD % | 3.05% |
Fund Inception | 11/11/2005 |
---|---|
Fund Manager | Anthony Cross / Julian Fosh |
TER | 1.88 (30-Nov-2013) |
Minimum Investment | |
---|---|
Initial | £2500 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | 5.00% |
Annual Mang't | 1.75% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.28 |
You are here: research